Potential for Alzheimer’s treatment with monoclonal antibodies

welcom in kemoj.com Potential for Alzheimer’s treatment with monoclonal antibodies.

 

Potential for Alzheimer’s treatment with monoclonal antibodies

In the recent issue of The New England Journal of Medicine, there is a report highlighting promising outcomes in the treatment of Alzheimer’s disease through the application of focused ultrasound technology to disrupt the blood-brain barrier. The study reveals that focused ultrasound can temporarily open the blood-brain barrier, facilitating the delivery of drugs. The research, conducted in collaboration with the WVU Rockefeller Neuroscience Institute (RNI), indicates that a combination of focused ultrasound and the delivery of monoclonal antibodies leads to a faster reduction of beta-amyloid plaque, a key characteristic of Alzheimer’s disease.

Insightec, a global healthcare company dedicated to transforming patient care through acoustic energy, announced the positive clinical study. The collaboration between researchers at RNI and Insightec demonstrates the potential of focused ultrasound in conjunction with systemic monoclonal antibody infusion for enhancing the removal of cerebral beta-amyloid. This innovative approach holds promise for targeted drug delivery not only in Alzheimer’s disease but also in other neurological conditions.

Maurice R. Ferré, MD, CEO, and chairman of the board at Insightec, emphasizes the opportunity for collaborations with drug companies to improve drug delivery to the brain. He notes that only a small percentage of drugs can traditionally cross the blood-brain barrier, making progress challenging and patient safety a concern with large systemic drug concentrations. The ability of focused ultrasound to disrupt the blood-brain barrier showcases its potential in addressing complex neurological conditions.

The proof-of-concept study’s encouraging results pave the way for advancements in combating Alzheimer’s disease, according to Ali Rezai, MD, executive chair of RNI. The longstanding collaboration between RNI and Insightec has played a crucial role in accelerating progress in treating patients with Alzheimer’s disease and other neurological conditions.

With 6.7 million Americans affected by Alzheimer’s disease, the emergence of promising therapies is crucial in addressing this unmet medical need. The breakthrough discovery in focused ultrasound technology not only opens new avenues for research but also instills renewed hope for patients and their families. As research continues, there is anticipation that this treatment approach will evolve and refine, offering even more effective treatments.

Importantly, neither the manufacturer of the ultrasound device (Insightec, Tirat Carmel, Israel) nor the manufacturer of aducanumab (Biogen, Cambridge, USA) sponsored the research or participated in any aspect of study design, data collection, analysis, interpretation, or manuscript writing. This ensures the objectivity and independence of the study.

 

Insightec is a global healthcare organization at the forefront of shaping the future of patient care through the innovative application of acoustic energy. The company’s Exablate Neuro platform employs focused sound waves, guided safely by MRI, to deliver effective tremor treatment for patients dealing with medication-refractory essential tremor and Parkinson’s disease. Ongoing research partnerships with prominent academic and medical institutions are exploring additional applications in the neuroscience field. Headquartered in Haifa, Israel, and Miami, Insightec also maintains offices in Dallas, Shanghai, and Tokyo.

The West Virginia University Rockefeller Neuroscience Institute (RNI) is a distinguished multidisciplinary institute dedicated to patient care, education, and research. With 250 faculty members spanning five departments and over 1,500 professionals providing neurological and mental health care to 275,000 patients annually, RNI is committed to advancing brain health and therapeutics. Utilizing cutting-edge technologies and collaborating with both academic and industry partners, the RNI team addresses public health challenges ranging from addiction to Alzheimer’s disease. For more details about the WVU Rockefeller Neuroscience Institute, visit WVUMedicine.org/RNI.

Forward-looking Statements: This document includes forward-looking statements related to plans, expectations, and future events. Expressions such as “may,” “can,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “promise,” “continue,” “ongoing,” or their negatives may identify forward-looking statements. These statements involve inherent risks, uncertainties, and other factors that could lead to actual results differing materially from those expressed or implied. Insightec bases any forward-looking statement on information available as of the statement’s date, and the organization does not commit to updating or revising any forward-looking statement to reflect changes in circumstances or expectations.

 

Read more***

thomas piketty biography

.